Research

UCSF: Proactive, Personalized, Precise: AI and Collaborative Research is Revolutionizing ALS Care

May 1, 2025 Comments Off on UCSF: Proactive, Personalized, Precise: AI and Collaborative Research is Revolutionizing ALS Care

With no single known cause, no definitive diagnostic test and no cure, ALS remains a tragically confounding neurodegenerative disease. Its progression varies dramatically from patient to patient, leaving clinicians and…

ALS News Today: Brain-computer Interface to Restore Speech Named Award Winner

April 28, 2025 Comments Off on ALS News Today: Brain-computer Interface to Restore Speech Named Award Winner

A neurosurgeon and his team from the University of California (UC) Davis Health have won The Herbert Pardes Clinical Research Excellence Award — given by the nonprofit Clinical Research Forum — for…

ALS News Today: First Patient Dosed in a Phase 1 Study Testing AMX0114 in ALS

April 21, 2025 Comments Off on ALS News Today: First Patient Dosed in a Phase 1 Study Testing AMX0114 in ALS

The first patient has been dosed in a Phase 1 clinical study testing AMX0114, an experimental therapy being developed by Almylyx Pharmaceuticals for amyotrophic lateral sclerosis (ALS). The treatment targets calpain-2, a protein believed to…

ALS News Today: MDA 2025: INS1202 Gene Therapy Shows Promise In SOD1-ALS Mice

April 1, 2025 Comments Off on ALS News Today: MDA 2025: INS1202 Gene Therapy Shows Promise In SOD1-ALS Mice

A single dose of Insmed’s investigational gene therapy INS1202 preserved motor function and prolonged survival in a mouse model of amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations. The therapy was also found to…

Letters of Intent for ALS Research Funding Accepted April 15 – May 15

March 31, 2025 Comments Off on Letters of Intent for ALS Research Funding Accepted April 15 – May 15

The ALS Network, in partnership with ALS United, proudly announces that letters of intent for ALS research funding will be accepted April 15 – May 15, 2025.  “We are honored…

Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference

March 12, 2025 Comments Off on Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference

JERSEY CITY, N.J. March 12, 2025 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025…

Meet Karen DaSilva, MD, Queen’s Medical Center

March 7, 2025 Comments Off on Meet Karen DaSilva, MD, Queen’s Medical Center

Dr. Karen DaSilva has been practicing medicine since 2006. She worked at the Sansum Clinic since 2011, and then transferred to The Queen’s Health Systems. Dr. DaSilva received her medical…

ALS News Today: Fat molecules may limit damage to nerve cells in ALS, study finds

March 4, 2025 Comments Off on ALS News Today: Fat molecules may limit damage to nerve cells in ALS, study finds

Fat molecules called polyunsaturated fatty acids, or PUFAs, can help lessen nerve damage in amyotrophic lateral sclerosis (ALS), according to a study of fruit flies and cell models. Previous studies…

Springer Nature Link: Racial Disparities in the Diagnosis and Prognosis of ALS Patients in the United States

February 5, 2025 Comments Off on Springer Nature Link: Racial Disparities in the Diagnosis and Prognosis of ALS Patients in the United States

Recently studies have shown ALS in the United States to be more commonly diagnosed in White males over 60 years of age. Previous epidemiologic studies addressing racial variation in ALS…

Addressing Inequities in ALS Healthcare: The Critical Need for Diversity in Research

February 5, 2025 Comments Off on Addressing Inequities in ALS Healthcare: The Critical Need for Diversity in Research

ALS affects individuals across all backgrounds, yet representation in ALS research has long been skewed. Data reveals that approximately 95% of participants in previous ALS clinical trial studies were Caucasian,…